Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The promise of immunotherapy in genitourinary malignancies.

Zhang T, Armstrong AJ, George DJ, Huang J.

Precis Clin Med. 2018 Dec;1(3):97-101. doi: 10.1093/pcmedi/pby018. Epub 2018 Dec 19.

2.

Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.

Marciscano AE, Madan RA.

Curr Treat Options Oncol. 2018 Mar 8;19(3):16. doi: 10.1007/s11864-018-0523-3. Review.

PMID:
29520448
3.

Immunobiology and immunotherapy in genitourinary malignancies.

Tsiatas M, Grivas P.

Ann Transl Med. 2016 Jul;4(14):270. doi: 10.21037/atm.2016.06.29. Review.

4.

Immunotherapy for genitourinary tumors.

Nakayama T, Kitano S.

Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1. Review.

PMID:
30710374
5.

Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.

Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.

Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19.

PMID:
29056275
6.

Combination immunotherapy in genitourinary malignancies.

Hoffman-Censits J, Wilde L.

Curr Opin Urol. 2016 Nov;26(6):523-8. doi: 10.1097/MOU.0000000000000336. Review.

PMID:
27517637
7.

Immunotherapy in genitourinary malignancies.

Wattenberg MM, Fong L, Madan RA, Gulley JL.

Curr Opin Urol. 2016 Nov;26(6):501-7. doi: 10.1097/MOU.0000000000000331. Review.

8.

Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.

Siefker-Radtke A, Curti B.

Nat Rev Urol. 2018 Feb;15(2):112-124. doi: 10.1038/nrurol.2017.190. Epub 2017 Dec 5. Review.

PMID:
29205200
9.

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.

Shao Z, Wang AZ, George DJ, Zhang T.

Asian J Urol. 2016 Oct;3(4):268-277. doi: 10.1016/j.ajur.2016.08.013. Epub 2016 Sep 6. Review.

10.

Immunotherapy advances in uro-genital malignancies.

Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, de Braud F, Procopio G.

Crit Rev Oncol Hematol. 2016 Sep;105:52-64. doi: 10.1016/j.critrevonc.2016.06.012. Epub 2016 Jun 17. Review.

PMID:
27372200
11.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

PMID:
29405038
12.

Emerging role of checkpoint inhibition in localized bladder cancer.

Singh P, Black P.

Urol Oncol. 2016 Dec;34(12):548-555. doi: 10.1016/j.urolonc.2016.09.004. Epub 2016 Oct 21. Review.

PMID:
27776977
13.

Immune checkpoint inhibitors for metastatic bladder cancer.

Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A.

Cancer Treat Rev. 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31. Review.

PMID:
29407369
14.

Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.

Surolia I, Gulley J, Madan RA.

Expert Opin Biol Ther. 2014 Dec;14(12):1769-81. doi: 10.1517/14712598.2014.955010. Epub 2014 Sep 12. Review.

PMID:
25212872
15.

Checkpoint inhibitors in the treatment of urological malignancies.

Popovic LS, Matovina-Brko G, Popovic M.

ESMO Open. 2017 Jun 23;2(2):e000165. doi: 10.1136/esmoopen-2017-000165. eCollection 2017. Review.

16.

A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.

Hanna KS.

Pharmacotherapy. 2017 Nov;37(11):1391-1405. doi: 10.1002/phar.2033. Epub 2017 Oct 17. Review.

PMID:
28950037
17.

Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.

Ghatalia P, Zibelman M, Geynisman DM, Plimack ER.

Curr Treat Options Oncol. 2017 Jan;18(1):7. doi: 10.1007/s11864-017-0458-0. Review.

PMID:
28210995
18.

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.

Atkins MB, Clark JI, Quinn DI.

Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151. Review.

PMID:
28383639
19.

[Systemic immune checkpoint inhibition : A promising treatment for urological tumors?]

Roos FC, Becker C, Stope MB, Tsaur I; Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie.

Urologe A. 2018 May;57(5):583-590. doi: 10.1007/s00120-018-0622-6. Review. German.

PMID:
29569115
20.

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Alme AK, Karir BS, Faltas BM, Drake CG.

Urol Oncol. 2016 Apr;34(4):171-81. doi: 10.1016/j.urolonc.2016.01.006. Epub 2016 Feb 28. Review.

Supplemental Content

Support Center